Komori
Presentation materials for financial results5592Kusurinomadoguchi,Inc.Information and Communications, Services and Others

Financial Results Briefing Materials for the Fiscal Year Ending March 2026

For the fiscal year ending March 2026, recurring revenue from the Media business and Minna no Okusuribako business grew, and revenue, operating profit and net income all exceeded the previous fiscal year. The Core Systems business reported lower revenue and profit due to a reactionary decline in subsidy-related demand and upfront investment in new products, but consolidated results as a whole achieved higher revenue and profit.

Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
37
Year-on-year change in operating profit (%)
Wording
Definitive
How definitive the wording is.

Contents of this document

Presentation materials for financial resultsFiscal year ending March 202610 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥12,330 million+10.0%
Operating profit¥2,681 million+37.0%
Ordinary income¥2,666 million+37.0%
Net income¥2,952 million+45.0%
Operating profit margin22 %
Selling, general and administrative expenses¥4,288 million
Results for the three months of the current quarter
Net Sales
¥3,402 million+23.0%
Gross profit
¥1,886 million+28.0%
Operating profit
¥666 million+67.0%
Ordinary income
¥654 million+63.0%
Net income
¥839 million+78.0%
EBITDA
¥1,066 million+46.0%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Revenue and profit at each stage improved significantly from the initial plan
New initiatives
  • Acquisition of メディウェブ社
  • Expansion of healthcare and health-related services using EPARK Medication Handbook
  • Expansion of AI reception terminal deployment in the Media business
  • Planned release of the 3Bees Lite Plan
Key KPIsA metric the company considers important as a management benchmark.
  • Number of facilities24,539 Engagements
    Year on year against the same period last year+2171 facilities
  • Reservations7,377 thousand cases
  • Cumulative downloads of EPARK Medication Handbook7,051 thousand cases
    Year on year against the same period last year+422 thousand downloads
  • Total customers53,441 Customers
  • Gross profit from recurring revenue¥3,580 million+24.0%
  • Transaction value¥232,103 million-1.0%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Facility ARPU
¥15.9 thousand+7.0%
Total customers
53,441 Customers
Segment results
  • BusinessMedia Business
    Net Sales
    ¥5,020 million+15.0%
    Gross profit from recurring revenue
    ¥1,800 million+52.0%
  • BusinessMinna no Okusuribako business (medication procurement platform)
    Net Sales
    ¥3,540 million+13.0%
    Gross profit from recurring revenue
    ¥1,520 million+16.0%
  • BusinessCore Systems business
    Net Sales
    ¥3,480 million-1.0%
    Gross profit from recurring revenue
    ¥480 million-18.0%
Financial targets
ROE
29.8 %
Fiscal yearFiscal year ending March 2026
Market Size / Share
  • Target market for online prescription reservations4.5 100 million prescriptions
  • Company share1.6 %
  • Number of pharmacy locations6.3 10,000 stores
  • Company share39 %
Number of employees
Number of Employees531 people
Annual Dividend
¥38
Payout ratio
14.4 %
Contents of this document
ItemDetails
Document typePresentation materials for financial results
Fiscal Period CoveredFiscal year ending March 2026
Net Sales¥12,330 million (YoY +10.0%)
Operating profit¥2,681 million (YoY +37.0%)
Ordinary income¥2,666 million (YoY +37.0%)
Net income¥2,952 million (YoY +45.0%)
Operating profit margin22 %
Selling, general and administrative expenses¥4,288 million
Results for the three months of the current quarterNet Sales ¥3,402 million (YoY +23.0%) / Gross profit ¥1,886 million (YoY +28.0%) / Operating profit ¥666 million (YoY +67.0%) / Ordinary income ¥654 million (YoY +63.0%) / Net income ¥839 million (YoY +78.0%) / EBITDA ¥1,066 million (YoY +46.0%)
Self-assessment against the planRevenue and profit at each stage improved significantly from the initial plan
Segment resultsBusiness Media Business / Net Sales ¥5,020 million (YoY +15.0%) / Gross profit from recurring revenue ¥1,800 million (YoY +52.0%), Business Minna no Okusuribako business (medication procurement platform) / Net Sales ¥3,540 million (YoY +13.0%) / Gross profit from recurring revenue ¥1,520 million (YoY +16.0%), Business Core Systems business / Net Sales ¥3,480 million (YoY -1.0%) / Gross profit from recurring revenue ¥480 million (YoY -18.0%)
Key KPIs24,539 Engagements, 7,377 thousand cases, 7,051 thousand cases, 53,441 Customers, ¥3,580 million (YoY +24.0%), ¥232,103 million (YoY -1.0%)
Unit price and quantity metricsFacility ARPU ¥15.9 thousand (YoY +7.0%) / Total customers 53,441 Customers
Number of employeesNumber of Employees 531 people / Change during the period Not disclosed / Hiring plan Not disclosed
Financial targetsROE 29.8 %
Annual Dividend¥38
Payout ratio14.4 %
Market Size / Share4.5 100 million prescriptions, 1.6 %, 6.3 10,000 stores, 39 %
New initiativesAcquisition of メディウェブ社, Expansion of healthcare and health-related services using EPARK Medication Handbook, Expansion of AI reception terminal deployment in the Media business, Planned release of the 3Bees Lite Plan
Items this document does not state (12)
Gross Profit MarginFull-year earnings forecastProgress against full-year forecastBreakdown of Factors Affecting the ChangeNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The main driver was growth in stock revenue and stock gross profit in the Media business and Minna no Okusuribako business. One-off revenue declined following a reactionary decline from the exceptional demand in the previous fiscal year, but growth in the number of facilities and online prescription reservations, strong performance by the dead-stock inventory service, and the acquisition of procurement support customers contributed to results. SG&A expenses declined as the Group implemented cost reductions across the organization. Net income also benefited from the carryforward of tax loss carryforwards in connection with the absorption-type merger of a subsidiary in November 2024.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Briefing Materials for the Fiscal Year Ending March 2026 | Kusurinomadoguchi,Inc. (5592) timely disclosure | Komori